Morningside Ventures, a private equity firm, led a $17m Series A funding round in Neuroelectrics, a eveloper of non-invasive and high definition electrical brain stimulation technology designed for personalized neuromodulation. “By approaching disorders of the central nervous system using the natural signaling of the brain rather than focusing on one target and one receptor, we believe the Neuroelectrics approach could succeed in indications where traditional pharmaceuticals have had limited or no impact,” Stephen Bruso, Morningside.